title: Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
abstract: We measured the soluble IL-2 receptor alpha (sIL-2R alpha) in sera and in bone marrow of 20 patients with minimal residual hematological malignances, 6 of them with multiple myeloma (MM), 8 with Hodgkin's disease (HD) and 6 with non-Hodgkin's lymphoma (NHL), low grade. Compared to 10 normal individuals, HD and NHL group of patients had in sera significantly increased levels of sIL-2R alpha (252.8 +/- 42.9 versus 1437.2 +/- 1639 and 761.8 +/- 431 U/ml, respectively). After low-dose IL-2 given subcutaneously once daily at a dose of 1.8 x 10(6) U/patient for 3 weeks, additional significant increase in levels of IL-2R alpha was observed in sera and in bone marrow of patients with NHL (761.8 +/- 431 versus 2633 +/- 788 U/ml and 785 +/- 448 versus 2475 +/- 431 U/ml, respectively). The increase of sIL-2R alpha level after IL-2 therapy was also seen in sera and in bone marrow of HD and MM group; however, because of high standard deviation this increase was not statistically significant. We conclude that 1) in comparison to healthy subjects the levels of sIL-2R alpha remained elevated in HD and NHL patients, even at the stage of minimal residual disease (MRD) after intensive chemotherapy or radiotherapy, 2) the levels of sIL-2R alpha which appeared in sera and bone marrow of patients after IL-2 therapy seemed to be dependent on the type of hematological disorders.
authors.affiliation: Department of Virology and Immunology, Maria Curie-Skłodowska University, Lublin, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Kandefer-Szerszeń
authors.forename: W
authors.initials: W
authors.lastname: Legieć
authors.forename: A
authors.initials: A
authors.lastname: Dmoszyńska
authors.forename: W
authors.initials: W
authors.lastname: Rzeski
mesh_terms: D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000737:chemistry / Q000378:metabolism*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006689:Hodgkin Disease / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D006801:Humans; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D007958:Leukocyte Count / Q000187:drug effects; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D015375:Receptors, Interleukin-2 / Q000032:analysis / Q000096:biosynthesis* / Q000097:blood*; D012995:Solubility
chemical_list: D007376:Interleukin-2; D015375:Receptors, Interleukin-2